I rebuilt two published CHO cell-culture papers — a hybrid ODE + machine-learning growth model, and a genome-scale metabolic reduction pipeline — as an interactive digital twin that runs in…
The Every Company and Onego Bio are now fighting over recombinant ovalbumin in courts on two continents. The way this case resolves will shape how broadly IP rights can be…
If you’ve ever read a paper on lysine production with Corynebacterium glutamicum and thought “right, but what do I actually do on Monday morning when I’m standing in front of…
Look, I’ll be honest. For years I ran bioreactors the way most of us do: set your temperature, set your pH, watch the DO trace, take a sample every few…
The Gap Between Models and Tools I’ve seen a lot of impressive ML models in biopharma that never get used. Not because the science is wrong, but because the tool…
The Features That Matter After training the developability model on 100+ therapeutic antibodies, I looked at the feature importance rankings. The model had learned to weight certain properties more heavily…
Why Trastuzumab Is the Perfect Test Case When I built my antibody developability predictor, I knew I needed to validate it against a molecule where we actually know the manufacturing…
The Inflection Point Three-four years ago, I stood in front of production equipment I’d designed using textbook equations and decades-old heuristics. The systems worked—they always had—but I couldn’t shake the…
Kemal